Search

Your search keyword '"Hori, Shunta"' showing total 652 results

Search Constraints

Start Over You searched for: Author "Hori, Shunta" Remove constraint Author: "Hori, Shunta"
652 results on '"Hori, Shunta"'

Search Results

101. Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.

102. Clinical significance of limited and extended pelvic lymph node dissection during robot‐assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis.

103. Life sciences

106. Usefulness of clinical factors for diagnosing and differentiating types of testicular malposition in boys: A retrospective study

107. Video‐urodynamic effects of vibegron, a new selective β3‐adrenoceptor agonist, on antimuscarinic‐resistant neurogenic bladder dysfunction in patients with spina bifida

108. Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma

109. Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery.

110. Assessment of bladder function for stabilizing urinary volume overnight with recording of brain waves ( ABSORB study)

112. Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy

114. Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015

116. Additional file 1 of Remnant renal volume can predict prognosis of remnant renal function in kidney transplantation donors: a prospective observational study

117. This title is unavailable for guests, please login to see more information.

119. Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies

120. Hexylaminolevulinate‐mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer

121. Trends in the Treatment Outcomes and Features of Cryptorchidism in Boys: A Single-Institute Experience

122. ラット膀胱での水吸収におけるアクアポリン-2の役割

123. Clinical outcomes after intravesical bacillus Calmette–Guérin for the highest‐risk non‐muscle‐invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019

124. Photodynamic Diagnosis-Assisted En Bloc Transurethral Resection of Bladder Tumor for Nonmuscle Invasive Bladder Cancer: Short-Term Oncologic and Functional Outcomes

127. Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method

129. Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model

132. Periprostatic fat thickness quantified by preoperative magnetic resonance imaging is an independent risk factor for upstaging from cT1/2 to pT3 in robot‐assisted radical prostatectomy

133. Integrative assessment of clinicopathological parameters and the expression of PD‑L1, PD‑L2 and PD‑1 in tumor cells of retroperitoneal sarcoma

134. Effects of a new β3‐adrenoceptor agonist, vibegron, on neurogenic bladder dysfunction and remodeling in mice with spinal cord injury

135. Trends in treatment outcomes of hydrocele in Japanese children: A single‐institute experience

137. Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model

138. Biochemical control of the combination of cyclooxygenase‐2 inhibitor and 125 I‐brachytherapy for prostate cancer: Post hoc analysis of an open‐label controlled randomized trial

139. Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells

140. Initial experience of complete laparoscopic radical nephroureterectomy combined with transvesical laparoscopic excision of distal ureter in patients with upper urinary tract cancer

141. Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab

142. Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma

144. Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the Bladder

145. PDE5阻害薬であるタダラフィルは糖尿病ラットの膀胱血流を改善し、初期段階に低下する下部尿路機能を回復する

146. The effects of choreito on a model of nocturnal polyuria using Dahl salt‐sensitive rats.

147. Usefulness of clinical factors for diagnosing and differentiating types of testicular malposition in boys: A retrospective study.

148. Assessment of bladder function for stabilizing urinary volume overnight with recording of brain waves (ABSORB study).

149. Factors affecting urinary frequency after low‐dose‐rate brachytherapy for prostate cancer.

150. Video‐urodynamic effects of vibegron, a new selective β3‐adrenoceptor agonist, on antimuscarinic‐resistant neurogenic bladder dysfunction in patients with spina bifida.

Catalog

Books, media, physical & digital resources